drugset / Trial / NCT00916201
Evaluation Study of New Compounds With Potential Use in Schizophrenia
Phase 1
Withdrawn
Central Institute of Mental Health, Mannheim
Max Planck Institute for Metabolism Research · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.
Timeline
- Start
- 2025-01-31
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 320 mg | Oral |
| Subject | Insulin | Protein / enzyme biologic | 160 iu | Intranasal |
| Subject | URB597 | Small molecule | 10 mg | Oral |